Combined TLR4/MyD88 scores ≥5 significantly predicted lymph node metastasis (42.9% vs 28.3%, p=0.046) and high-grade tumor budding (p=0.002). Here, MYD88 is linked to metastatic malignant neoplasm in the lymph nodes.